Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 14/20 | 0.41 |
| ▸ | WNT1 | P04628 | 6/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK3 | P49761 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1175940 | 1.00 | GSK3B (0.42) | GSK3BCDK2GSK3ADYRK1AWNT1 | |
| Formic Acid SCHEMBL5563261 | 0.96 | GSK3B (0.40) | GSK3BCDK2GSK3ADYRK1AWNT1 | |
| SCHEMBL1176462 | 0.93 | CDK2 (0.48) | GSK3BCDK2GSK3ACHEK1HDAC3 | |
| SCHEMBL1176466 | 0.93 | CDK2 (0.48) | GSK3BCDK2GSK3ACHEK1HDAC3 | |
| Formic Acid SCHEMBL5562073 | 0.89 | CDK2 (0.46) | GSK3BCDK2GSK3ACHEK1HDAC3 | |
| SCHEMBL5046675 | 0.86 | DYRK1A (0.40) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL1176539 | 0.86 | DYRK1A (0.40) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL1175540 | 0.86 | DYRK1A (0.41) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL5038892 | 0.86 | DYRK1A (0.41) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL5042792 | 0.85 | DYRK1A (0.56) | GSK3BDYRK1AWNT1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396833-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-08 | — | — | US | claimed |
| EP-1697378-B1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2007-11-21 | — | — | EP | claimed |
| US-20110028483-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028483-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA1 | GSK3B 608/4885CDK2 1206/4885GSK3A 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.